PARP1 and neoplasm: The clinical utility of PARP inhibition lies in the concept of “synthetic lethality”, in which neither a mutation in HHR genes nor PARP inhibition, alone, would be lethal to a cell, but the combination of the two factors in tumor cells ensures cell death [16].